Haemonetics (HAE) Earnings Date & Reports

Key Takeaways

• Haemonetics reported fiscal second-quarter 2027 revenue of $357.8 million, up 9.3% year over year and ahead of the roughly $346.8 million consensus estimate.
• Adjusted earnings per share (EPS) rose 6% to $1.35, topping the $1.30 analyst consensus, while GAAP (Generally Accepted Accounting Principles) EPS climbed 23% to $1.00.
• Plasma revenue surged 16.5% to $162.6 million, driven by the expanding CSL relationship and broader adoption of the Persona Plus suite.
• Management raised full-year fiscal 2027 revenue guidance for the second straight quarter but lowered its operating-margin expansion target to reflect ramp-up investments.
• Free cash flow reached $104 million in the quarter, up 17%, as strong cash generation continued to strengthen the balance sheet.
• For more detail on this ticker's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated pages on Tickeron.
• Explore Trending AI Robots to discover AI-powered trading strategies and ideas across the market.

Earnings Context and Why It Matters

Haemonetics Corporation (NYSE: HAE) is a global healthcare company focused on blood and plasma collection, blood management, and hospital technologies. Its fiscal 2027 second quarter, which ended September 26, 2026, carries particular weight because it reflects the early economics of the company's expanded relationship with plasma leader CSL. Heading into the report, investors were watching whether accelerating plasma volumes could lift both revenue and profitability, especially after a strong stock run-up of roughly 48% since the prior earnings report. The results matter beyond a single quarter: they help validate whether Haemonetics can convert a major customer win into durable, multi-year growth while managing the cost of scaling up production and distribution capacity.

Reported Results

Haemonetics delivered a beat-and-raise quarter led by its plasma business. Net revenue increased 9.3% to $357.8 million, exceeding the consensus estimate of about $346.8 million. Adjusted EPS grew 6% to $1.35, ahead of the $1.30 consensus, while GAAP EPS rose 23.5% to $1.00. Organic revenue growth accelerated to 10% in the quarter, up from 6% in the first quarter.

By segment, Apheresis revenue rose 12.6% to $204.8 million, with plasma revenue up 16.5% to $162.6 million. MedSurg revenue increased 5.1% to $153 million. Adjusted gross margin expanded roughly 140 basis points (bps) to 61.9%, though that figure included an approximately 200 bps benefit from a tariff refund; excluding that one-time item, gross margin was essentially flat. Adjusted operating margin came in at 26.3%, down 40 bps year over year, as operating expenses rose 15% on investments tied to growth initiatives, higher performance-based compensation, and increased freight costs.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical companion for earnings-focused research. If you want to identify ideas aligned with your own criteria, explore the AI Screener to streamline your market analysis.

Market Reaction and Investor Sentiment

Haemonetics entered the report near a 52-week high, with shares around $127 after a significant post-earnings rally earlier in the fiscal year, which raised the bar for a positive reaction. The company's second consecutive beat-and-raise quarter supported the growth narrative, but the market's focus has shifted toward profitability quality. A margin guide-down, driven partly by a non-recurring tariff refund benefit and rising costs tied to the CSL ramp, tempered the headline strength. Investors are weighing the faster-than-expected revenue acceleration against the reality that earnings are not yet growing at the same pace, creating a more balanced sentiment heading into the remainder of fiscal 2027.

Forward Outlook and Key Factors to Monitor

Haemonetics raised its full-year fiscal 2027 outlook, now expecting reported revenue growth of 8% to 11% and organic revenue growth of 6% to 9%, both up from prior guidance. However, the company lowered its adjusted operating-margin expansion target to 0 to 50 bps from 50 to 100 bps, reflecting investments made ahead of expected plasma share gains.

Looking ahead, investors should monitor the timing and economics of the CSL rollout, where Nexus PCS devices with the full Persona Plus suite are expected to reach all of CSL's U.S. plasma centers by the end of calendar 2027. Management has indicated the relationship could add roughly 40% to 50% to plasma volumes over time. Because contract economics are weighted toward the fourth quarter, second-half growth and margin performance depend heavily on successful execution of these conversions.

Additional factors to watch include gross margin trends as ramp-up production costs are capitalized into inventory, ongoing cost pressures from freight, fuel, and performance-based compensation, and progress in MedSurg, where growth moderated as the TEG 5000 capital cycle winds down. Free cash flow conversion, now guided above 80% of adjusted net income, will also be a key indicator of how efficiently the company funds its growth.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations